The Journal of the Pharmacy Society of Wisconsin
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Submit a Manuscript
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact

Risk of Acute Kidney Injury with Sodium-Glucose Cotransporter-2 Inhibitors in Elderly and Very Elderly Adults Compared to the General Adult Population

by Kenina E. Silvera, 2024 PharmD Candidate, Michael W. Nagy, PharmD, BCACP

Question: In the general adult population, elderly adults, and very elderly adults, what is the risk of acute kidney injury (AKI) with sodium-glucose cotransporter-2 (SGLT2) inhibitors versus placebo?

"Sodium-glucose cotransporter-2 (SGLT2) inhibitors are used to treat type 2 diabetes mellitus (T2DM) by inhibiting there absorption of filtered glucose in the proximal convoluted tubules of the kidney, promoting urinary excretionof glucose. The five SGLT2 inhibitors approved by the FDA are: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and bexaglifloxin. Some of these agents have additionally gained approval for the use in other disease states, including heart failure and chronic kidney disease (CKD)."


Keywords: Sodium-Glucose Transporter 2 Inhibitors, Canagliflozin, Empagliflozin, Diabetes Mellitus, Type 2, Dapagliflozin, Ertugliflozin, Aldosterone, Creatinine, Renin, Diuretics, Incidence, Standard of Care, Renal Dialysis, Kidney, Renal Insufficiency, Acute Kidney Injury, Aging, Heart Failure, Diuresis, Hospitalizations​

Download PDF

2023 November/December Table of Contents 

The Journal of the Pharmacy Society of Wisconsin (ISSN 2837-8229)


Past Issues

2023
2020
2021
​2022

2019
2018
2017

About PSW

www.pswi.org

Contact Us

thejournal@pswi.org
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Submit a Manuscript
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact